Global Antibody-Drug Conjugates Market Size To Overtake USD

0

Pune, India, September 28, 2021 (GLOBE NEWSWIRE) – According to MarketStudyReport, Worldwide antibody-drug conjugates market, valued at $ 4.3 billion in 2020, is expected to post a 23% CAGR over 2021-2027 and amass a valuation of $ 18.31 billion by the end of the forecast period.

The report comprises individual assessment of different market segmentations including technology landscape, application spectrum, and regional scope. It takes into account the factors that shape the growth of each segment, along with their projected market share and growth rate over the estimated period.

Continuing further, the study examines the competitive arena of the global Antibody Conjugate industry by profiling the major competitors with particular emphasis on the strategies they have implemented to assist stakeholders in make informed decisions that generate solid profits over the forecast period.

Request a copy of this report @ https://www.marketstudyreport.com/request-a-sample/4164345/

The increasing prevalence of cancer and the burgeoning geriatric population who are at increased risk of contracting the disease are catalyzing the growth of the market. In fact, the World Cancer Observatory claims that 19.3 million cancer cases were recorded in 2020, with a death toll of around 9.96 million. In addition, the incidence of cancer is expected to reach 21.9 million by 2025 and 24.6 million by 2030.

For the uninitiated, the antibody-drug conjugate is a kind of biopharmaceutical drug specially designed as a targeted therapy for the treatment of cancer. There is a strong pipeline for these drugs and other technological advances will continue to present new opportunities for companies in this field.

However, fluctuating raw material prices and strict regulations regarding quality standards can negatively impact industry dynamics over the forecast span.

Overview of geographic scope:

The major regional contributors to the global antibody-drug conjugate industry are North America, Latin America, Asia-Pacific, and Europe. Among these, North America holds the lead in industry growth, attributable to the presence of leading players and high R&D spending in the region.

Meanwhile, the size of the Asia-Pacific market is expected to grow rapidly through 2027 due to the increasing number of cancer cases and increasing R&D investment.

Summary of the competitive landscape:

ADC Therapeutics SA, GlaxoSmithKline Plc, Daiichi Sankyo Co. Ltd., Seagen Inc., Astellas Pharma Inc., Gilead Sciences Inc., Astrazeneca plc, Pfizer Inc., F. Hoffmann-La Roche Ltd. and Takeda Pharmaceutical Co. Ltd. are leading companies impacting global Antibody-Drug Conjugates industry trends.

To access a sample copy or view this report in detail and the table of contents, please click on the link below:

https://www.marketstudyreport.com/reports/global-antibody-drug-conjugate-market-size-research

Industry players are focused on product development and marketing agreements / partnerships with regulatory authorities and other companies in order to expand their product portfolio and subsequently amplify profits. In addition, they also undertake mergers and acquisitions to significantly expand their presence.

Technology Landscape of Global Antibody-Drug Conjugates Market (Revenue, USD Billion, 2018-2027)

  • Linker less
  • Cleavable linker
  • Non-cleavable linker

Application Spectrum of Global Antibody-Drug Conjugates Market (Revenue, USD Billion, 2018-2027)

  • Multiple myeloma
  • Leukemia
  • Breast cancer
  • Urothelial cancer and bladder cancer
  • Others

Geographic Bifurcation of Global Antibody-Drug Conjugates Market (Revenue, USD Billion, 2018-2027)

North America

Europe

  • Spain
  • France
  • Germany
  • UK
  • Italy
  • The rest of europe

Asia Pacific

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific

Latin America

Rest of the world

Global Antibody and Drug Conjugates Market Company Profiles (Revenue, USD Billion, 2018-2027)

  • ADC Therapeutics SA
  • GlaxoSmithKline Plc
  • Daiichi Sankyo Co. Ltd.
  • Seagen Inc.
  • Astellas Pharma inc.
  • Gilead Sciences Inc.
  • Astrazeneca plc
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltée.
  • Takeda Pharmaceutical Co. Ltd.

Contents:

Chapter 1. Executive summary

1.1. Market Snapshot

1.2. Global and Segmental Market Estimates and Forecasts, 2019-2027 (USD Billion)

1.2.1. Antibody-Drug Conjugates Market, by Region, 2019-2027 (USD Billion)

1.2.2. Antibody-Drug Conjugates Market, by Technology, 2019-2027 (USD Billion)

1.2.3. Antibody-Drug Conjugates Market, by Application, 2019-2027 (USD Billion)

1.3. Key trends

1.4. Estimation methodology

1.5. Research hypothesis

Chapter 2. Definition and Scope of Global Antibody-Drug Conjugates Market

2.1. Goal of the study

2.2. Definition and scope of the market

2.2.1. Scope of the study

2.2.2. Evolution of the industry

2.3. Years taken into account for the study

2.4. Currency conversion rates

Chapter 3. Global Antibody-Drug Conjugates Market Dynamics

3.1. Antibody-Drug Conjugates Market Impact Analysis (2019-2027)

3.1.1. Market factors

3.1.1.1. Growing geriatric population

3.1.1.2. Increased incidence and prevalence of cancer

3.1.2. Market restriction

3.1.2.1. High cost of manufacturing antibody-drug conjugates and challenges in downstream processing of ADCs

3.1.2.2. Strict refund policies for ADCs

3.1.3. Market opportunities

3.1.3.1. Presence of a strong product pipeline

Chapter 4. Global Antibody-Drug Conjugates Market Analysis

4.1. Model 5 Force de Porter

4.1.1. Bargaining power of suppliers

4.1.2. The bargaining power of buyers

4.1.3. The threat of new participants

4.1.4. The threat of substitutes

4.1.5. Competitive rivalry

4.1.6. Futuristic approach to Porter’s 5 forces model (2018-2027)

4.2. PEST analysis

4.2.1. Politics

4.2.2. Economic

4.2.3. Social

4.2.4. Technological

4.3. Investment adoption model

4.4. Analyst recommendation and conclusion

Chapter 5. Global Antibody-Drug Conjugates Market, By Technology

5.1. Market Snapshot

5.2. Global Antibody-Drug Conjugates Market by Technology, Performance – Potential Analysis

5.3. Global Antibody-Drug Conjugates Market Estimates & Forecasts by Technology 2018-2027 (USD Billion)

5.4. Antibody-Drug Conjugates Market, Sub-Segment Analysis

5.4.1. Cleavable linker

5.4.2. Non-cleavable linker

5.4.3. Linker less

Chapter 6. Global Antibody-Drug Conjugates Market, By Application

a. Market Snapshot

6.1. Global Antibody-Drug Conjugates Market by Application, Performance – Potential Analysis

6.2. Global Antibody-Drug Conjugates Market Estimates & Forecasts by Application 2018-2027 (USD Billion)

6.3. Antibody-Drug Conjugates Market, Sub-Segment Analysis

6.3.1. Leukemia

6.3.2. Multiple myeloma

6.3.3. Breast cancer

6.3.4. Urothelial cancer and bladder cancer

6.3.5. Others

Chapter 7. Global Antibody-Drug Conjugates Market, Regional Analysis

Related report:

Connected Drug Delivery Devices Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share, and Forecast, 2021-2027

The connected drug delivery devices market is expected to grow significantly by 2027 due to technological advances in the sector. In addition, the increasing incidence of chronic diseases around the world is expected to further fuel the market demand during the forecast period. The growing preference for home care among patients requiring regular treatment has spurred the expansion of the industry in recent years. Additionally, the increased efficiency of connected drug delivery devices compared to manual devices has increased market adoption. Major industry players have implemented lucrative techniques to tap emerging markets through product launches, collaborations, mergers and acquisitions, which have positively impacted market dynamics. From a regional perspective, the connected drug delivery devices market in Latin America accounted for nearly 9.9% of the overall industry revenue in 2020. Meanwhile, the delivery devices market of connected medicines in the Middle East and Africa is expected to show robust growth through 2027, growing at a CAGR of over 35.9% over the study period.

Global Research Antibodies with COVID-19 Impact Market Size Study and Regional Forecast 2020-2027

Global Research Antibodies Market to reach USD 17.02 billion by 2027. The global research antibody market is valued at approximately USD 10.52 billion in 2019 and is expected to grow with a healthy growth rate of over 6.20% during the forecast period 2020-2027. The antibody is also called immunoglobulin, a protein produced by plasma cells in response to certain antigens. Antibodies have a wide range of therapeutic applications as well as diagnostic purposes for several indications including inflammatory and infectious diseases, autoimmune diseases and cancer, etc. Global spread of COVID-19 is dramatically driving the growth of research antibody market due to rising demand for COVID-19 antibody detection kits. COVID-19 antibody detection kits play an essential role in determining who is infected. It is specially designed for the detection and diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgM / IgG antibodies in human serum, plasma or blood.

About Us:

Market Study Report is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services together in one place.

Our clients partner with Market Study Report to facilitate their research and evaluation of market intelligence products and services and in turn focus on the core activities of their business.

If you are looking for research reports on global or regional markets, information on competition, emerging markets and trends or if you are just looking to stay on top of the trend then market research report. is the platform that can help you achieve any of these goals.



        


Source link

Leave A Reply

Your email address will not be published.